Cat. No.: HY-N7102

Ceftiofur

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Ceftiofur is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.

For research use only. We do not sell to patients.

Purity: 99.81%
CAS No.: 80370-57-6
Formula: C₁₉H₁₇N₅O₇S₃
Molecular Weight:523.56

Storage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Ceftiofur Chemical Structure

CAS No.: 80370-57-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Antibiotic Isoforms :

All NF-κB Isoforms :

All p38 MAPK Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	35.7 μM Compound: Ceftiofur	Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins	[PMID: 23344796]

In Vitro

Ceftiofur (1, 5, 10 mg/L; pretreatment for 1 h+LPS stimulation for 12 h) can significantly inhibit the secretion of TNF-α, IL-1β, and IL-6 in RAW 264.7 cells, but has no significant effect on the secretion of IL-10^[2].
Ceftiofur (1, 5, 10 mg/L; pretreatment for 1 h+LPS stimulation for 30 min) can significantly inhibit the phosphorylation of ERK, JNK, and p38 and the nuclear translocation of NF-κB p65 in RAW 264.7 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

RAW 264.7 cells
Concentration:

1, 5, 10 mg/L
Incubation Time:

1 h pretreatment with Ceftiofur followed by 30 min LPS stimulation
Result:

Dramatically decreased the phosphorylation levels of ERK, JNK, and p38 in Ceftiofur-treated cells compared to the LPS-treated control cells, while the total protein levels of MAPKs showed no change.

Immunofluorescence^[2]

Cell Line:

RAW 264.7 cells
Concentration:

1, 5, 10 mg/L
Incubation Time:

1 h pretreatment with Ceftiofur followed by 30 min LPS stimulation
Result:

Nuclear translocation of NF-κB p65 induced by LPS was strongly inhibited in a dose-dependent manner in Ceftiofur-pretreated cells.

In Vivo

Ceftiofur (20 mg/kg; sc; single dose; 1 h before or 0/1 h after 30 mg/kg LPS challenge) significantly improves the survival rate of mice in the endotoxemia model of female C57BL/6 mice, and reduces the levels of plasma TNF-α, IL-1β, and IL-6, and increases the level of IL-10^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C57BL/6 mice (18-20 g, 6-8 weeks old) with LPS-induced endotoxemia model^[3]
Dosage:

20 mg/kg Ceftiofur (dissolved in saline)
Administration:

Subcutaneous injection, single dose, administered 1 h before or 0, 1, 4, 12 h after intraperitoneal injection of 30 mg/kg LPS.
Result:

Pretreatment with 20 mg/kg Ceftiofur 1 h before LPS challenge significantly increased the survival rate of mice (70% survival at 144 h vs. 0% in LPS control group).
When administered 0 or 1 h after LPS injection, Ceftiofur still provided significant protection, but protection decreased when delayed to 4 h and was absent at 12 h.
Plasma levels of TNF-α, IL-1β, and IL-6 in Ceftiofur-pretreated mice were significantly lower than those in the LPS control group at specific time points (1 h for TNF-α, 3 h for IL-6, 12 h for IL-1β), while IL-10 levels were significantly higher at 1 h after LPS challenge.

Chemical Information

CAS No. 80370-57-6
Appearance Solid
Molecular Weight 523.56
Formula C₁₉H₁₇N₅O₇S₃
Color White to off-white
SMILES

O=C(C(N12)=C(CSC(C3=CC=CO3)=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (4)

All

Sort by:

Journal Impact Factor

Nat Commun

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]

2020 Apr 14;11(1):1792. PMID: 32286289
Mol Syst Biol

Benchmarking AlphaFold-enabled molecular docking predictions for antibiotic discovery. [Abstract]

2022 Sep;18(9):e11081. PMID: 36065847
Microorganisms

Isolation, Antimicrobial Susceptibility, and Genotypes of Three Pasteurellaeae Species Prevalent on Pig Farms in China Between 2021 and 2023. [Abstract]

2025 Apr 18;13(4):938. PMID: 40284774
Vet Microbiol

Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]

2024 May:292:110046. PMID: 38471428

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (191.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9100 mL

9.5500 mL

19.1000 mL

5 mM

0.3820 mL

1.9100 mL

3.8200 mL

10 mM

0.1910 mL

0.9550 mL

1.9100 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Salmon SA, et al. In vitro activity of Ceftiofur and its primary metabolite, desfuroylCeftiofur, against organisms of veterinary importance. J Vet Diagn Invest. 1996 Jul;8(3):332-6. [Content Brief]

[2]. Ci X, et al. Ceftiofur impairs pro-inflammatory cytokine secretion through the inhibition of the activation of NF-kappaB and MAPK. Biochem Biophys Res Commun. 2008 Jul 18;372(1):73-7. [Content Brief]

[3]. Ci X, et al. Ceftiofur regulates LPS-induced production of cytokines and improves LPS-induced survival rate in mice. Inflammation. 2008 Dec;31(6):422-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9100 mL	9.5500 mL	19.1000 mL	47.7500 mL
	5 mM	0.3820 mL	1.9100 mL	3.8200 mL	9.5500 mL
	10 mM	0.1910 mL	0.9550 mL	1.9100 mL	4.7750 mL
	15 mM	0.1273 mL	0.6367 mL	1.2733 mL	3.1833 mL
	20 mM	0.0955 mL	0.4775 mL	0.9550 mL	2.3875 mL
	25 mM	0.0764 mL	0.3820 mL	0.7640 mL	1.9100 mL
	30 mM	0.0637 mL	0.3183 mL	0.6367 mL	1.5917 mL
	40 mM	0.0478 mL	0.2388 mL	0.4775 mL	1.1938 mL
	50 mM	0.0382 mL	0.1910 mL	0.3820 mL	0.9550 mL
	60 mM	0.0318 mL	0.1592 mL	0.3183 mL	0.7958 mL
	80 mM	0.0239 mL	0.1194 mL	0.2388 mL	0.5969 mL
	100 mM	0.0191 mL	0.0955 mL	0.1910 mL	0.4775 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ceftiofur

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Pyroptosis Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

EMA-Approved Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Animal Drug Library

FDA Kinase Inhibitor Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Ceftiofur

All Antibiotic Isoforms

All NF-κB Isoforms

All p38 MAPK Isoforms

All TNF Receptor Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ceftiofur Related Classifications

HY-N7102 Related Classifications